Kwality Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Kwality Pharmaceuticals es Ramesh Arora, nombrado en Jan 2016, tiene una permanencia de 8.83 años. posee directamente un 26.9% de las acciones de la empresa, con un valor de ₹2.48B. La antigüedad media del equipo directivo y de la junta directiva es de 8.8 años y 8.9 años, respectivamente.

Información clave

Ramesh Arora

Chief Executive Officer (CEO)

₹6.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8.8yrs
Participación del CEO	26.9%
Permanencia media de la dirección	8.8yrs
Promedio de permanencia en la Junta Directiva	8.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Ramesh Arora (70 yo)

8.8yrs

Permanencia

₹6,000,000

Compensación

Mr. Ramesh Arora has been the Managing Director and Executive Director of Kwality Pharmaceuticals Limited since January 16, 2016 and May 4, 1983 respectively. Mr. Arora has more than 3 decades of experienc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ramesh Arora	MD & Director	8.8yrs	₹6.00m	26.9% ₹ 2.5b
Aditya Arora	CFO & Whole Time Director	8.8yrs	₹4.20m	11.95% ₹ 1.1b
Ajay Arora	Whole Time Director	no data	₹6.00m	13.59% ₹ 1.3b
Anju Arora	Whole Time Director	no data	₹2.40m	1.31% ₹ 120.7m
Geeta Arora	Whole Time Director	no data	₹2.40m	1.07% ₹ 99.2m
Gurpreet Kaur	Company Secretary & Compliance Officer	5.3yrs	sin datos	sin datos
Shankar Dayal	Chief Domestic Sales Officer	no data	sin datos	sin datos

8.8yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 539997 es experimentado (8.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ramesh Arora	MD & Director	41.5yrs	₹6.00m	26.9% ₹ 2.5b
Aditya Arora	CFO & Whole Time Director	9.1yrs	₹4.20m	11.95% ₹ 1.1b
Ajay Arora	Whole Time Director	29.3yrs	₹6.00m	13.59% ₹ 1.3b
Anju Arora	Whole Time Director	14.1yrs	₹2.40m	1.31% ₹ 120.7m
Geeta Arora	Whole Time Director	14.1yrs	₹2.40m	1.07% ₹ 99.2m
Kiran Verma	Non-Executive Independent Director	8.8yrs	₹180.00k	sin datos
Pankaj Takkar	Non-Executive Independent Director	8.8yrs	₹108.00k	0.029% ₹ 2.7m
Ravi Singh	Non-Executive Independent Director	8.8yrs	₹20.00k	sin datos
Kartik Kapur	Independent Director	3.8yrs	₹20.00k	sin datos
Prashanth Vellanki	Non-Executive & Independent Director	1.7yrs	₹7.00k	sin datos

8.9yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 539997 se considera experimentada (8.9 años de antigüedad promedio).

Kwality Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 24, 2024

Insufficient new directors

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Less than half of directors are independent

Recent updates

Second quarter 2025 earnings released: EPS: ₹8.15 (vs ₹5.99 in 2Q 2024)

Investor sentiment improves as stock rises 19%

Kwality Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 30, 2024

New minor risk - Share price stability

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 24, 2024

Investor sentiment improves as stock rises 28%

First quarter 2025 earnings released: EPS: ₹8.04 (vs ₹5.10 in 1Q 2024)

Kwality Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 10, 2024

Full year 2024 earnings released: EPS: ₹22.76 (vs ₹18.67 in FY 2023)

Kwality Pharmaceuticals Limited to Report Q4, 2024 Results on May 23, 2024

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: ₹7.39 (vs ₹6.82 in 3Q 2023)

Insufficient new directors

Kwality Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Kwality Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 04, 2023

Kwality Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹5.10 (vs ₹9.99 in 1Q 2023)

Kwality Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹18.16 (vs ₹116 in FY 2022)

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ₹6.82 (vs ₹15.20 in 3Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director

Second quarter 2023 earnings released: EPS: ₹8.82 (vs ₹57.33 in 2Q 2022)

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 30, 2023

Investor sentiment improved over the past week

First quarter 2023 earnings released

Kwality Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

Investor sentiment improved over the past week

Kwality Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 28, 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

CFO & Whole Time Director recently bought ₹1.3m worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2022 earnings released: EPS ₹90.57 (vs ₹6.70 in 1H 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹14.60 (vs ₹8.02 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: ₹61.15

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹49.00

Kwality Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 13, 2020

Kwality Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2020

Kwality Pharmaceuticals Limited to Report Second Half, 2020 Results on Jul 13, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad